Cytori Therapeutics, Inc. (CYTX) - Financial and Strategic SWOT Analysis Review

Description: Cytori Therapeutics, Inc. (CYTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cytori Therapeutics, Inc. (Cytori Therapeutics) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. Cytori has two key product lines, namely, the Celution System family which comprises medical devices for use in cosmetic and reconstructive surgery and StemSource family for use in laboratory research and stem cell banking. The company offers its products to the physicians and patients at the point-of-care by its proprietary technologies and products. The company markets its cellular therapeutics under the trade name, Cytori Cell Therapy. Cytori Therapeutics is headquartered in San Diego, California, the US.

Cytori Therapeutics, Inc. Key Recent Developments

Apr 18, 2016: Cytori Strengthens Global Patent Portfolio
Mar 23, 2016: Cytori Granted SME Status by European Medicines Agency
Mar 03, 2016: Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results
Feb 08, 2016: Cytori Reports Interim Data on U.S. Phase II Osteoarthritis Trial
Oct 22, 2015: Cytori Third Quarter Financial Results Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and
presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents:

List of Tables
List of Figures
Section 1 - About the Company
  Cytori Therapeutics, Inc. - Key Facts
  Cytori Therapeutics, Inc. - Key Employees
  Cytori Therapeutics, Inc. - Key Employee Biographies
  Cytori Therapeutics, Inc. - Major Products and Services
  Cytori Therapeutics, Inc. - History
  Cytori Therapeutics, Inc. - Company Statement
  Cytori Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
  Cytori Therapeutics, Inc. - Business Description
  Cytori Therapeutics, Inc. - Corporate Strategy
  Cytori Therapeutics, Inc. - SWOT Analysis
  SWOT Analysis - Overview
  Cytori Therapeutics, Inc. - Strengths
    Strength - Proprietary Celution Technology
    Strength - Operational Base
    Strength - Patent Portfolio
  Cytori Therapeutics, Inc. - Weaknesses
Weakness - History of Losses
Weakness - Decline in Product Revenue

Cytori Therapeutics, Inc. - Opportunities
Opportunity - Growing Market for Reconstructive Surgery
Opportunity - Product Approvals
Opportunity - New Contract Initiatives
Opportunity - Orphan Drug Designation

Cytori Therapeutics, Inc. - Threats
Threat - Competition and Technological Changes
Threat - Industry Consolidation
Threat - Health Insurance Reimbursement Risks

Cytori Therapeutics, Inc. - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart

Section 4 – Company's Lifesciences Financial Deals and Alliances
Cytori Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cytori Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Cytori Therapeutics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Cytori Therapeutics, Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
Cytori Therapeutics, Inc., Recent Deals Summary

Section 5 – Company's Recent Developments
Apr 18, 2016: Cytori Strengthens Global Patent Portfolio
Mar 23, 2016: Cytori Granted SME Status by European Medicines Agency
Mar 03, 2016: Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results
Feb 08, 2016: Cytori Reports Interim Data on U.S. Phase II Osteoarthritis Trial
Oct 22, 2015: Cytori Third Quarter Financial Results Update
Sep 08, 2015: Cytori Appoints VP and General Manager of Cell Therapy
Sep 03, 2015: Enrollment Begins in Cytori Phase III/Pivotal ADRESU Urinary Incontinence Trial
Aug 06, 2015: Cytori Reports Second Quarter 2015 Business and Financial Results
Jul 29, 2015: Cytori Appoints VP of Business Development and General Counsel
May 11, 2015: Cytori Reports First Quarter 2015 Business and Financial Results

Section 6 – Appendix

Methodology
Ratio Definitions
About us
Contact Us
Disclaimer

List of Tables
Cytori Therapeutics, Inc., Key Facts
Cytori Therapeutics, Inc., Key Employees
Cytori Therapeutics, Inc., Key Employee Biographies
Cytori Therapeutics, Inc., Major Products and Services
Cytori Therapeutics, Inc., History
Cytori Therapeutics, Inc., Subsidiaries
Cytori Therapeutics, Inc., Key Competitors
Cytori Therapeutics, Inc., Ratios based on current share price
Cytori Therapeutics, Inc., Annual Ratios
Cytori Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cytori Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Cytori Therapeutics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Cytori Therapeutics, Inc., Medical Equipment, Deals By Type, 2010 to YTD 2016
Cytori Therapeutics, Inc., Recent Deals Summary

Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Cytori Therapeutics, Inc., Ratio Charts
Cytori Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cytori Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Cytori Therapeutics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Cytori Therapeutics, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2565172/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cytori Therapeutics, Inc. (CYTX) - Financial and Strategic SWOT Analysis Review
Web Address: http://www.researchandmarkets.com/reports/2565172/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>□</td>
<td>USD 125</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>□</td>
<td>USD 250</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>□</td>
<td>USD 375</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof

First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World